Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A-Reference-Cited by-同舟云学术

Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

Published:2013-09-15 Issue:10 Volume:19 Page:1318-1324
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Pandey Gouri Shankar, ,Yanover Chen,Miller-Jenkins Lisa M,Garfield Susan,Cole Shelley A,Curran Joanne E,Moses Eric K,Rydz Natalia,Simhadri Vijaya,Kimchi-Sarfaty Chava,Lillicrap David,Viel Kevin R,Przytycka Teresa M,Pierce Glenn F,Howard Tom E,Sauna Zuben E

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3270.pdf

Reference22 articles.

1. Lillicrap, D. Improvements in factor concentrates. Curr. Opin. Hematol. 17, 393–397 (2010).

2. Wight, J. & Paisley, S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9, 418–435 (2003).

3. Gouw, S.C. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119, 2922–2934 (2012).

4. Jenkins, P.V. et al. Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. Blood 84, 2197–2201 (1994).

5. Egler, C. et al. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity. J. Mol. Recognit. 22, 301–306 (2009).

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A;International Journal of Molecular Sciences;2024-03-24

2. Frequency of natural regulatory T cells specific for factor VIII in the peripheral blood of healthy donors;European Journal of Immunology;2024-03

3. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

4. A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII;Heliyon;2023-06

5. Race, ethnicity, F8 variants, and inhibitor risk: analysis of the “My Life Our Future” hemophilia A database;Journal of Thrombosis and Haemostasis;2023-04